Compare Ginkgo Bioworks Holdings Inc (DNA) vs Charles Schwab Corporation Common Stock (SCHW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Charles Schwab Corporation Common Stock — how do they compare? Ginkgo Bioworks Holdings Inc trades at $7.33 (market cap $505.73M), while Charles Schwab Corporation Common Stock trades at $109.2 (market cap $186.25B). The key difference: Charles Schwab Corporation Common Stock is far larger — about 368.3× Ginkgo Bioworks Holdings Inc's market cap, and Charles Schwab Corporation Common Stock pays a 1.19% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | SCHW | |
|---|---|---|
Market Cap | $505.73M | $186.25B |
Sector | Health | Financials |
52-Week High | $16.14 | $108.02 |
52-Week Low | $5.48 | $85.35 |
Enterprise Value | $607.68M | — |
Dividend Yield | — | 1.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $7.42, down 3.01% with bearish technical signals. The company reported Q2 2026 revenue of $20M, down 48% year-over-year, while maintaining a high gross margin of 68.04% but significant net losses. Analyst sentiment is mixed with 45% buy ratings amid ongoing business model transition to autonomous laboratory systems and contract research services.
The outlook remains challenging with persistent revenue declines and negative cash flow, though recent earnings beats provide some optimism. Key risks include execution of the business pivot and path to profitability. Wall Street shows cautious optimism with majority buy ratings despite fundamental headwinds.
Charles Schwab (SCHW) trades at $108.63, up 0.59% today, approaching its all-time high of $109.05. The stock shows strong momentum with three consecutive quarterly earnings beats and bullish technical indicators. Revenue grew to $23.92B in 2025 with net income margin expanding to 38.79%. Recent news highlights institutional buying and positive analyst coverage, though an insider sale and ongoing litigation present minor concerns.
Outlook remains positive with analyst consensus target of $122.33 suggesting 12.6% upside. Strong earnings growth, improving cash flow trends, and market leadership position support further appreciation. Key risks include market sensitivity to interest rates, competitive pressures, and potential regulatory impacts from ongoing litigation. The stock offers growth potential but requires monitoring of macroeconomic conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →
